Category: Medicine

3 Stocks That Are Ridiculously Cheap Right Now

With the market steadily pushing above and beyond its all-time highs, it’s becoming increasingly difficult to find stocks with compelling valuations. With this in mind, we asked three of our contributors which stocks they think are still bargains that might be worth buying right now.

Biotech Stock Mailbag: Puma’s Rebound Explained, TG Therapeutics Approval Debate, Aurinia Next Steps

This week’s Biotech Stock Mailbag will address some current controversies and burning questions in our little corner of the investment world. Why the hell is Puma Biotechnology trading higher after the successful readout of Roche’s “APHINITY’ study of Perjeta in adjuvant breast cancer? What are the arguments for and against TG Therapeutics securing approval for ublituximab in high-risk chronic lymphocytic leukemia ? Did Aurinia Pharmaceuticals make a change to the primary endpoint of its phase III study of voclosporin in lupus nephritis? Are regulators okay with it? The March 2 announcement by Roche that Perjeta met the primary endpoint in the APHINITY study caused Puma shares to fall from $38 to an intraday low of $29.

Daily Dividend Report: PBA, PLCE, AMGN, SPLS, VGR

Pembina Pipeline announced today that its Board of Directors declared a common share cash dividend for March 2017 of $0.16 per share to be paid, subject to applicable law, on April 15, 2017 to shareholders of record on March 25, 2017. The Children’s Place, the largest pure-play children’s specialty apparel retailer in North America, today announced that its Board of Directors has approved a new $250 million share repurchase program and has increased the Company’s quarterly dividend to $0.40 per share from $0.20 per share.

Wednesday’s ETF with Unusual Volume: XT

The iShares Exponential Technologies ETF is seeing unusually high volume in afternoon trading Wednesday, with over 637,000 shares traded versus three month average volume of about 73,000. Shares of XT were trading flat on the day.

Snap Slumps 12%, Closes at Lowest Since IPO

Shares of Snap Inc slumped 12 percent on Monday and closed at their lowest level of the three sessions since the Snapchat owner’s soaring market debut last week. The $3.4-billion listing last Thursday was the hottest technology offering in three years, but the loss-making company’s lofty valuation and slowing user growth have raised eyebrows on Wall Street.

There’s one key factor that shows why organic milk is…

But as it turns out, there may be one type of milk that’s nutritionally superior: the organic kind that comes from grass-fed animals. Michael Tunick, a research chemist at the U.S. Department of Agriculture and author of ” The Science of Cheese ,” told Business Insider that the difference has to do with what the cows eat.

Is This The Best Biotech Play for 2017?

Last year, a political spotlight on drug pricing policies threatened the entire industry. Scandals at Mylan and Valeant Therapeutics did damage to the entire sector, sending the share prices of many biotech companies down.

Roche’s Perjeta Succeeds in Key Aphinity Breast Cancer Study

Roche Holding AG’s breast cancer medicine Perjeta succeeded in the drugmaker’s most hotly anticipated patient study, bolstering a franchise that could exceed $9 billion in sales by 2021. Patients who took Perjeta alongside chemotherapy and Roche’s own Herceptin drug after surgery for early breast cancer had a reduced risk of dying or seeing their breast tumors return than those on the older treatments alone, the Swiss drugmaker said in a statement Thursday.

Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan

Shares of Impax Laboratories were down 19% to $11.50 in premarket trading on Wednesday after the company reported results and said it is not issuing 2017 guidance for total revenue and EPS because of ongoing revenue volatility in its generics unit. The Fort Washington, Pa.-based firm reported fourth-quarter adjusted earnings per share of 16 cents on revenue of $198.4 million.

Is Illumina On The Verge of a Breakout?

Illumina has been tracing out a narrow consolidation pattern for the last seven weeks. Yesterday’s impressive 4.25% gain, which was the second-best performance in the Nasdaq 100, may soon spark an end to this bullish pennant formation with a fresh rally leg.

A Few Names on my Radar on This Softness

Momentum has slowed for the second day in a row, but the tendency has been some late buying that produces a strong close. With overseas markets operating on Monday when the U.S. is closed, there may be a little reluctance to add new inventory.

Millions to fight food industry sway, from a snack bar CEO

A $25 million pledge to fight the food industry’s influence on public health is coming from a surprising source – the CEO of a snack bar maker. Kind founder Daniel Lubetzky says he’s pledging his own money to create a group called “Feed the Truth” dedicated to revealing corporate influence in the nutrition field, with activities like education campaigns and investigative journalism.

Gilead and ‘Good News’ Make A Rare, Joint Appearance at HIV Conference

With sales of its hepatitis C drugs falling and an oncology pipeline that has largely disappointed, bictegravir is vitally important for Gilead to defend and grow its dominant HIV franchise. Bictegravir, the company’s next-generation integrase inhibitor, suppressed the HIV virus in newly diagnosed patients better than dolutegravir, a similar, rival drug from GlaxoSmithKline , according to results from a mid-stage clinical trial announced Monday night.

Why Sage Therapeutics Jumped Today

Sage Therapeutics announced top-lineresults froma Phase 2 clinical trial study of SAGE-217, the company’s orally administereddrug that is being researched as a hopeful treatment of major depressive disorder . Data from the trial showed that SAGE-217 met the study’s primary endpoint, which was to evaluate that the drug was safe and well-tolerated by patients.

Allergan Bets on Aesthetics With $2.48 Billion Zeltiq Deal

Botox maker Allergan Plc is betting on aesthetics with the $2.48 billion acquisition of fat-chilling device maker Zeltiq Aesthetics Inc., doubling down on a lucrative industry where patients pay mostly in cash for products and services. The purchase price is $56.50 a share in cash, the companies said Monday in a statement, a 14 percent premium to Pleasanton, California-based Zeltiq’s closing price Friday of $49.40.

Teva Said to Consider Options for Branded Generics Unit

Israeli drugmaker Teva Pharmaceutical Industries Ltd. is weighing options including a sale of its branded generics products business as it works to reduce debt, according to people familiar with the matter. The business could be valued at several billion dollars, and Teva may also consider spinning off the unit, the people said, asking not to be identified because the deliberations are private.

Why Intercept Pharmaceuticals’ Latest News Caused the Stock to Jump

So when the companyannounced on Friday morning that it was making a significant change to its late-stage clinical study of obeticholic acid in treating NASH, investors were eager to find out what’s going on. Intercept’s phase 3 REGENERATE clinical trial initially had two co-primary endpoints: fibrosis improvement with no worsening of NASH and NASH resolution with no worsening of fibrosis.

Why Ocular Therapeutix Inc Jumped Higher Today

Analyst Elemer Piros is excited about Ocular Therapeutix’s near-term potential to get Dextenza approved to treat post-surgical pain. Last month, Ocular Therapeutix resubmitted its application for Dextenza to the Food and Drug Administration after being issued a complete response letter — the FDA’s euphemism for a rejection — last July.

Why bluebird bio Stock Surged 20.7% Higher in January

After updating investors on its wide-ranging gene therapy research program at a key industry conference early in the month,shares of bluebird bio At the J.P. Morgan Healthcare Conference in early January, Bluebird Bio’s management outlined how it hopes to transform treating rare disease, including cerebral ALD , transfusion dependent beta thalassemia , and sickle cell disease. The company provided an outlook for 2022 that includes a goal of having two gene therapies on the market, two other therapies near commercialization, and four or more research programs in clinical studies.

Compass Minerals Posts a Double Win

Diversification can help companies like Compass weather tough conditions in one market, but every once in a while, good conditions in both markets can bring a nice positive surprise. Coming into Wednesday’s fourth-quarter financial report, Compass investors expected to see a big boost in revenue but a drop in net income.

Gilead’s Biggest Blockbusters Are Fading Fast, Biotech Warns

Gilead Sciences Inc.’s massive hepatitis C franchise is fading, the company warned Tuesday, projecting that sales this year could be just two-thirds of what investors had been expecting. Revenue from the company’s drugs for the viral infection will be $7.5 billion to $9 billion in 2017, Gilead said in a statement.

Why Crisper Therapeutics Tumbled 12.4% in January

However, ongoing uncertainty about who owns the rights to this intellectual property may have contributed to shares slipping12.4% last month,according to S&P Global Market Intelligence . Crisper Therapeutics is one of a small group of new biotech start-ups that are researching CRISPR-Cas9, an approach that could potentially reshape disease caused by genetic mutation.

Earnings Preview: GlaxoSmithKline Likely to See Currency Boost; Advair Sales in Focus

GlaxoSmithKline reports fourth-quarter earnings Wednesday, with investors looking for guidance on the fate of its key Advair drug and the recent pace of organic growth for new products sales. GlaxoSmithKline Plc reports fourth-quarter earnings Wednesday, with investors looking for guidance on the fate of its key Advair drug in the U.S. and the recent pace of organic growth for new products sales.